cmi_logo.png
[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
December 11, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
Full Logo - OKYO .jpg
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
October 23, 2024 07:00 ET | OKYO Pharma LTD
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...
cmi_logo.png
[Latest] Global Cosmetic Pigments Market Size/Share Worth USD 4.9 Billion by 2033 at a 6.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
June 24, 2024 09:40 ET | Custom Market Insights
Austin, TX, USA, June 24, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cosmetic Pigments Market Size, Trends and Insights By Type (Surface Treated...
RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
February 22, 2024 06:05 ET | RetinalGeniX Technologies, Inc.
RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
roche-logo-blue.png
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
February 01, 2024 01:03 ET | F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
December 01, 2023 12:32 ET | RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO Virender Ahluwalia will serve as Interim Chief Financial Officer
Corza Medical's Ophthalmology Center of Technology and Innovation
Corza Medical Opens State-of-the-Art Ophthalmology Center of Technology and Innovation, Demonstrating Commitment to Global Eye Care Community
November 30, 2023 08:05 ET | Corza Medical Inc.
Corza Medical opens a new Ophthalmology Center of Technology and Innovation in MO to develop next-gen devices for eye treatments and enhance R&D.
IIA Logo_Segment-Beauty.png
SBLA BEAUTY Eye Lift Wand Recognized With “Eye Treatment Product Of The Year ” Award From Beauty Innovation
November 15, 2023 08:00 ET | Beauty Innovation Awards
LOS ANGELES, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The 2023 Beauty Innovation Awards today announced that the Eye Lift Wand from SBLA BEAUTY has been selected as “Eye Treatment Product Of The Year” in...
New Logo.png
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
November 13, 2023 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
November 09, 2023 12:58 ET | RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration and Alzheimer’s Syndrome.